{{Rsnum
|rsid=10801935
|Gene=VTCN1
|Chromosome=1
|position=117179265
|Orientation=plus
|GMAF=0.3838
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=VTCN1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 41.6 | 42.5 | 15.9
| HCB | 68.6 | 27.0 | 4.4
| JPT | 57.5 | 40.7 | 1.8
| YRI | 4.8 | 42.2 | 53.1
| ASW | 17.5 | 50.9 | 31.6
| CHB | 68.6 | 27.0 | 4.4
| CHD | 73.4 | 22.0 | 4.6
| GIH | 36.6 | 44.6 | 18.8
| LWK | 9.1 | 43.6 | 47.3
| MEX | 55.2 | 32.8 | 12.1
| MKK | 1.9 | 36.5 | 61.5
| TSI | 32.7 | 45.5 | 21.8
| HapMapRevision=28
}}
[[rs10801935]] is a SNP in the V-set domain containing T cell activation inhibitor 1 [[VTCN1]] gene, which is also known as B7-H4. 

A study of 500 Chinese Han women with breast cancer (and an equal number of matched controls) concluded that the [[rs10801935]](C;C) genotype showed a significantly decreased risk of [[breast cancer]] (odds ratio 0.328, CI: 0.145-0.739).{{PMID|19903360|OA=1
}}

{{PMID Auto
|PMID=24125968
|Title=An investigation of the effects of FGFR2 and B7-H4 polymorphisms in breast cancer
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}